Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.
XBI vs XLV: how they differ
XBI and XLV hold 8% of their weight in the same names, and XBI returned more over the year.
State Street(R) SPDR(R) S&P(R) Biotech ETF and State Street(R) Health Care Select Sector SPDR(R) ETF.
What they hold in common
By the books each fund has filed, XBI and XLV hold 8% of their money in the same securities at the same weight.
| Holding | XBI | XLV |
|---|---|---|
| REGENERON PHARMACEUTICALS | 1.27% | 1.33% |
| GILEAD SCIENCES INC | 1.15% | 3.01% |
| VERTEX PHARMACEUTICALS INC | 1.14% | 2.19% |
| ABBVIE INC | 1.09% | 7.54% |
| AMGEN INC | 1.09% | 3.46% |
| MODERNA INC | 2.87% | 0.81% |
| BIOGEN INC | 1.07% | 0.53% |
| INCYTE CORP | 1.13% | 0.35% |
| SSI US GOV MONEY MARKET CLASS | 0.08% | 0.19% |
| US DOLLAR | 0.02% | 0.02% |
| Only in XBI | Only in XLV |
|---|---|
| TWIST BIOSCIENCE CORP 1.81% | ELI LILLY + CO 14.87% |
| HALOZYME THERAPEUTICS INC 1.47% | JOHNSON + JOHNSON 10.73% |
| NATERA INC 1.46% | MERCK + CO. INC. 5.98% |
| KYMERA THERAPEUTICS INC 1.45% | UNITEDHEALTH GROUP INC 5.90% |
| TRAVERE THERAPEUTICS INC 1.40% | THERMO FISHER SCIENTIFIC INC 3.75% |
| ROIVANT SCIENCES LTD 1.39% | ABBOTT LABORATORIES 3.01% |
| ORUKA THERAPEUTICS INC 1.38% | PFIZER INC 2.64% |
| REVOLUTION MEDICINES INC 1.36% | BRISTOL MYERS SQUIBB CO 2.18% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 10, 2026.
| XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | XLV State Street(R) Health Care Select Sector SPDR(R) ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | State Street | State Street |
| What it is | SPDR S&P Biotech | Health care |
| Total return, 1 year | +64.0% | +20.4% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +46.5 pts | +2.9 pts |
| Expense ratio | 0.35% | 0.08% |
| Already in the S&P 500 | 8.5% | 100.0% |
| Holdings | 154 | 63 |
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Sep 10, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 154 positions, with the top ten at 15.9%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
XLV in plain words
XLV is an index equity fund tracking the Health care. Over the year to Sep 11, 2026 it returned +20.4% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.08% a year. By its holdings filed for Sep 10, 2026, 100% of the fund by weight is stocks the S&P 500 also holds, across 63 positions, with the top ten at 60.9%. It sat 5.9% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, XBI or XLV?
- In the year to Sep 13, 2026, with distributions reinvested, XBI returned +64.0% and XLV returned +20.4%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, XBI or XLV?
- XBI charges 0.35% a year and XLV charges 0.08%, so XLV is cheaper. Fees come from each fund's prospectus.
- How much do XBI and XLV overlap with the S&P 500?
- By their latest filed holdings, 8% of XBI and 100% of XLV by weight is stocks the S&P 500 already holds. Between the two funds, 8% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, XBI against XLV, data as of Sep 13, 2026. https://etfiq.com/compare/any/xbi-vs-xlv Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources